Skip to main content
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. — Investor Relations & Filings

Ticker · GLUE ISIN · US61225M1027 US Manufacturing
Filings indexed 324 across all filing types
Latest filing 2024-02-14 Major Shareholding Noti…
Country US United States of America
Listing US GLUE

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops small molecule precision medicines known as molecular glue degraders (MGDs). The company's proprietary drug discovery platform is engineered to rationally design MGDs that leverage the body's natural protein disposal system to selectively eliminate disease-causing proteins. This approach targets proteins that have been historically considered "undruggable" or are inadequately addressed by existing therapies. By integrating expertise in chemistry, artificial intelligence, structural biology, and proteomics, Monte Rosa is advancing a pipeline of therapeutic candidates primarily for cancer and other serious diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
MONTE ROSA THERAPEUTICS, INC.
Major Shareholding Notification
2024-02-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 8, 2024, by Monte Rosa Therapeutics, Inc. It includes a corporate update and a presentation from the J.P. Morgan Healthcare Conference. The text explicitly states that the press release and presentation are furnished as exhibits to this Form 8-K. The document is relatively short (3816 characters) and primarily serves as a disclosure of the corporate update and conference presentation rather than containing detailed financial statements or comprehensive financial analysis. According to the rules, such a filing is a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full financial report or detailed financial data itself. It also does not fit the criteria for other specific categories like Earnings Release or Investor Presentation since it is a Form 8-K filing with exhibits. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-01-08 English
FORM 4 SUBMISSION
Director's Dealing
2024-01-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.